In HCC, STING agonists can induce the activation and maturation of DCs and reprogram immunosuppressive macrophages into immune-activating subtypes, thereby increasing CD8+ T cells in the TME (Jing et al., 2019; Chen C. et al., 2021). Here, CD8A is linked to hepatocellular carcinoma.